Stock of Zevra Therapeutics, Inc. (ZVRA) is climbing roughly 19 percent on Tuesday morning trading after GeneDx announced a new genetic testing program with Zevra to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in Niemann-Pick Disease type C.
The company's shares are currently trading at $10.83 on the Nasdaq, up 18.75 percent. The stock opened at $9.12 and has climbed as high as $11.40 so far in today's session. Over the past year, it has traded in a range of $6.19 to $13.16.
Through this program, eligible patients in the United States will have access to genomic testing via GeneDx to help confirm or rule out a diagnosis of NPC.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.